FDA PMA FDA Class 3 Approved 🇺🇸 United States

Device, Hemostasis, Vascular

PMA: P990037 · Supplement: S024 · Decision Dec 22, 2006
Classifications
1
FEI Numbers
33
Registration Numbers
33

Basic Information

Device Name
Device, Hemostasis, Vascular
Trade Name
VASCULAR SOLUTIONS D-STAT FLOWABLE HEMOSTAT
PMA Number
P990037
Supplement Number
S024
Device Class
FDA Class 3
Product Code
MGB
Generic Name
Device, hemostasis, vascular
Medical Specialty
Unknown
Advisory Committee
Cardiovascular
Decision
Approved
Decision Code
APPR
Decision Date
December 22, 2006
Date Received
June 22, 2006
Supplement Type
Panel Track
Supplement Reason
Change Design/Components/Specifications/Material
Expedited Review
N
Docket Number
07M-0188

Advisory Committee Statement

APPROVAL FOR A NEW INDICATION FOR USE FOR THE D-STAT FLOWABLE HEMOSTAT. THE DEVICE IS INDICATED FOR USE IN HIGH-RISK ANTI-COAGULATED PATIENTS UNDERGOING IMPLANTATION OF A PULSE GENERATOR (E.G., PACEMAKER OR ICD) TO REDUCE THE FREQUENCY OF CLINICALLY RELEVANT HEMATOMA FORMATION IN THE PREPECTORAL POCKET. D-STAT FLOWABLE IS INDICATED FOR USE IN HIGH-RISK ANTI-COAGULATED PATIENTS UNDERGOING IMPLANTATION OF A PULSE GENERATOR (E.G., PACEMAKER OR ICD TO REDUCE THE FREQUENCY OF CLINICALLY RELEVANT HEMATOMA FORMATION IN THE PREPECTORAL POCKET. HIGH-RISK PATIENTS ARE DEFINED AS THOSE WHOSE ANTI-COAGULATION REGIMENS WILL RESUME WITHIN 24 HOURS OF IMPLANT. CLINICALLY RELEVANT HEMATOMAS ARE DEFINED AS THOSE THAT RESULT IN AN ALTERATION IN THE STANDARD OF CARE RESULTANT OF HEMATOMA FORMATION INCLUDING ALTERATION (I.E. SUSPENSION OR DISCONTINUATION) OF THE ANTICOAGULANT THERAPY REGIMEN (HEPARIN, LMWH, WARFARIN, OR CLOPIDOGREL), APPLICATION OF A COMPRESSION BANDAGE AND EVACUATION OF THE HEMATOMA.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
MGB Device, Hemostasis, Vascular